Berenberg Bank reiterated their buy rating on shares of AstraZeneca (LON:AZN - Free Report) in a research report report published on Monday morning, Marketbeat.com reports. They currently have a GBX 140 ($1.75) target price on the biopharmaceutical company's stock.
AZN has been the subject of a number of other research reports. Shore Capital reissued a "buy" rating on shares of AstraZeneca in a research report on Thursday, November 7th. JPMorgan Chase & Co. restated an "overweight" rating and set a £140 ($174.65) target price on shares of AstraZeneca in a research report on Friday, November 22nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, AstraZeneca has a consensus rating of "Moderate Buy" and a consensus price target of GBX 7,935.67 ($99.00).
Get Our Latest Stock Report on AstraZeneca
AstraZeneca Price Performance
Shares of LON AZN traded down GBX 44 ($0.55) during midday trading on Monday, reaching £106.68 ($133.08). 2,940,155 shares of the company were exchanged, compared to its average volume of 2,717,664. The stock's 50-day moving average price is £105.36 and its 200-day moving average price is £116.94. The stock has a market cap of £165.35 billion, a P/E ratio of 3,386.67, a PEG ratio of 0.86 and a beta of 0.17. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 84.97. AstraZeneca has a one year low of GBX 9,461 ($118.03) and a one year high of £133.88 ($167.02).
Insiders Place Their Bets
In other AstraZeneca news, insider Tony Mok purchased 1,500 shares of the company's stock in a transaction that occurred on Tuesday, November 19th. The shares were acquired at an average price of £126.80 ($158.18) per share, with a total value of £190,200 ($237,275.45). Also, insider Pascal Soriot purchased 20,000 shares of the business's stock in a transaction on Thursday, November 14th. The shares were bought at an average price of £102.03 ($127.28) per share, with a total value of £2,040,600 ($2,545,658.68). Corporate insiders own 0.04% of the company's stock.
AstraZeneca Company Profile
(
Get Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Articles
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
